Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of futibatinib (TAS-120) in advanced solid tumors with FGF/FGFR aberrations
jRCT2080224117Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Oct 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of futibatinib in Nonhematologic neoplasms and intrahepatic cholangiocarcinoma (ICC), sponsored by Taiho Pharmaceutical Co., Ltd. Started Oct 2018; status: completed.
02
Drugs
futibatinib
03
Conditions
Nonhematologic neoplasmsintrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on jRCT2080224117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224117.